当前位置: 首页 >> 检索结果
581. In type 2 diabetes, the effectiveness and side effects of GLP-1 RAs vary.
Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410. 38286487.
582. SCCM issued recommendations for corticosteroid use in acutely ill adults with sepsis, ARDS, or CAP.
Chaudhuri D, Nei AM, Rochwerg B, et al. 2024 focused update: guidelines on use of corticosteroids in sepsis, acute respiratory distress syndrome, and community-acquired pneumonia. Crit Care Med. 2024;52:e219-e233. 38240492.
583. The Safety of Outpatient Health Care : Review of Electronic Health Records.
作者: David M Levine.;Ania Syrowatka.;Hojjat Salmasian.;David M Shahian.;Stuart Lipsitz.;Jonathan P Zebrowski.;Laura C Myers.;Merranda S Logan.;Christopher G Roy.;Christine Iannaccone.;Michelle L Frits.;Lynn A Volk.;Sevan Dulgarian.;Mary G Amato.;Heba H Edrees.;Luke Sato.;Patricia Folcarelli.;Jonathan S Einbinder.;Mark E Reynolds.;Elizabeth Mort.;David W Bates.
来源: Ann Intern Med. 2024年177卷6期738-748页
Despite considerable emphasis on delivering safe care, substantial patient harm occurs. Although most care occurs in the outpatient setting, knowledge of outpatient adverse events (AEs) remains limited.
584. In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo.
Roubille F, Bouabdallaoui N, Kouz S, et al. Low-dose colchicine in patients with type 2 diabetes and recent myocardial infarction in the COLchicine Cardiovascular Outcomes Trial (COLCOT). Diabetes Care. 2024;47:467-470. 38181203.
585. In HFpEF with obesity, semaglutide improved health status and weight loss at 52 wk, regardless of initial health status.
Kosiborod MN, Verma S, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators. Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial. Circulation. 2024;149:204-216. 37952180.
586. In older patients with AF and frailty, switching from VKA to NOAC therapy increased a composite of major or CRNM bleeding at 12 mo.
Joosten LP, van Doorn S, van de Ven PM, et al. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation. 2024;149:279-289. 37634130.
587. In AF, CHA2DS2-VASc 1 subgroups did not differ for predicting risk for arterial thromboembolism at 1 y.
Østergaard L, Olesen JB, Petersen JK, et al. Arterial thromboembolism in patients with atrial fibrillation and CHA2DS2-VASc 1: a nationwide study. Circulation. 2024;149:764-773. 38152890.
588. In community-acquired pneumonia, adding oral clarithromycin to standard care increased early clinical response.
Giamarellos-Bourboulis EJ, Siampanos A, Bolanou A, et al. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2024;12:294-304. 38184008.
589. New use of thiazide diuretics vs. nonthiazide antihypertensive drugs was linked to hyponatremia over 2 y.
Andersson NW, Wohlfahrt J, Feenstra B, et al. Cumulative incidence of thiazide-induced hyponatremia: a population-based cohort study. Ann Intern Med. 2024;177:1-11. 38109740.
590. In mild ischemic stroke or high-risk TIA, DAPT started ≤72 h after onset reduced new stroke and increased bleeding at 90 d.
Gao Y, Chen W, Pan Y, et al; INSPIRES Investigators. Dual antiplatelet treatment up to 72 hours after ischemic stroke. N Engl J Med. 2023;389:2413-2424. 38157499.
591. The Benefits and Risks of Receiving Investigational Solid Tumor Drugs in Randomized Trials : A Systematic Review and Meta-analysis.
作者: Renata Iskander.;Hannah Moyer.;Dean Fergusson.;Sean McGrath.;Andrea Benedetti.;Jonathan Kimmelman.
来源: Ann Intern Med. 2024年177卷6期759-767页
Many patients participate in cancer trials to access new therapies. The extent to which new treatments produce clinical benefit for trial participants is unclear.
592. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease.
作者: Fu-Shun Yen.;Chii-Min Hwu.;Jia-Sin Liu.;Yi-Ling Wu.;Keong Chong.;Chih-Cheng Hsu.
来源: Ann Intern Med. 2024年177卷6期693-700页
No studies have reported the long-term outcomes of initiating sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with estimated glomerular filtration rates less than 20 mL/min/1.73 m2 to predialysis.
593. Excessive Alcohol Use and Alcohol Use Disorders: A Policy Brief of the American College of Physicians.
Alcohol is used by more people in the United States than tobacco, electronic nicotine delivery systems, or illicit drugs. Several health conditions, including cancer, cardiovascular disease, and liver disease, are associated with excessive alcohol use and alcohol use disorder. Nearly 30 million people aged 12 years or older in the United States reported past-year alcohol use disorder in 2022, but-despite its prevalence-alcohol use disorder is undertreated. In this policy brief, the American College of Physicians outlines the health effects of excessive alcohol use and alcohol use disorder, calls for policy changes to increase the availability of treatment of alcohol use disorder and excessive alcohol use, and recommends alcohol-related public health interventions.
594. Historical Redlining and Present-Day Nonsuicide Firearm Fatalities.
作者: Ayesha Dholakia.;Kendall J Burdick.;Catherine Kreatsoulas.;Michael C Monuteaux.;Jennifer Tsai.;S V Subramanian.;Eric W Fleegler.
来源: Ann Intern Med. 2024年177卷5期592-597页
Redlining began in the 1930s with the Home Owners' Loan Corporation (HOLC); this discriminatory practice limited mortgage availability and reinforced concentrated poverty that still exists today. It is important to understand the potential health implications of this federally sanctioned segregation.
595. Effect of Health Service Area on Primary Care Physician Provision of Low-Value Cancer Screening.
作者: Kassandra Dindinger-Hill.;Joshua Horns.;Jacob Ambrose.;Jeffrey Vehawn.;Mouneeb Choudry.;Trevor C Hunt.;Jonathan Chipman.;Benjamin Haaland.;Jiaming Li.;Heidi A Hanson.;Brock O'Neil.
来源: Ann Intern Med. 2024年177卷5期583-591页
Using a health systems approach to investigate low-value care (LVC) may provide insights into structural drivers of this pervasive problem.
596. Comparison of Hospital Mortality and Readmission Rates by Physician and Patient Sex.
作者: Atsushi Miyawaki.;Anupam B Jena.;Lisa S Rotenstein.;Yusuke Tsugawa.
来源: Ann Intern Med. 2024年177卷5期598-608页
Little is known as to whether the effects of physician sex on patients' clinical outcomes vary by patient sex.
597. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.
作者: Tyler Drake.;Adrienne Landsteiner.;Lisa Langsetmo.;Roderick MacDonald.;Maylen Anthony.;Caleb Kalinowski.;Kristen Ullman.;Charles J Billington.;Anjum Kaka.;Shahnaz Sultan.;Timothy J Wilt.
来源: Ann Intern Med. 2024年177卷5期618-632页
Newer diabetes medications may have beneficial effects on mortality, cardiovascular outcomes, and renal outcomes.
598. Assessing Clinician Utilization of Next-Generation Antibiotics Against Resistant Gram-Negative Infections in U.S. Hospitals : A Retrospective Cohort Study.
作者: Jeffrey R Strich.;Ahmed Mishuk.;Guoqing Diao.;Alexander Lawandi.;Willy Li.;Cumhur Y Demirkale.;Ahmed Babiker.;Alex Mancera.;Bruce J Swihart.;Morgan Walker.;Christina Yek.;Maniraj Neupane.;Nathaniel De Jonge.;Sarah Warner.;Sameer S Kadri.; .
来源: Ann Intern Med. 2024年177卷5期559-572页
The U.S. antibiotic market failure has threatened future innovation and supply. Understanding when and why clinicians underutilize recently approved gram-negative antibiotics might help prioritize the patient in future antibiotic development and potential market entry rewards.
599. Cost-Effectiveness of Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians.
作者: John T Schousboe.;Adrienne Landsteiner.;Tyler Drake.;Shahnaz Sultan.;Lisa Langsetmo.;Anjum Kaka.;Maylen Anthony.;Charles J Billington.;Caleb Kalinowski.;Kristen Ullman.;Timothy J Wilt.
来源: Ann Intern Med. 2024年177卷5期633-642页
In the United States, costs of antidiabetes medications exceed $327 billion.
600. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians.
作者: Amir Qaseem.;Adam J Obley.;Tatyana Shamliyan.;Lauri A Hicks.;Curtis S Harrod.;Carolyn J Crandall.; .;Ethan M Balk.;Thomas G Cooney.;J Thomas Cross.;Nick Fitterman.;Jennifer S Lin.;Michael Maroto.;Matthew C Miller.;Paul Shekelle.;Jeffrey A Tice.;Janice E Tufte.;Itziar Etxeandia-Ikobaltzeta.;Jennifer Yost.
来源: Ann Intern Med. 2024年177卷5期658-666页
The American College of Physicians (ACP) developed this clinical guideline to update recommendations on newer pharmacologic treatments of type 2 diabetes. This clinical guideline is based on the best available evidence for effectiveness, comparative benefits and harms, consideration of patients' values and preferences, and costs.
|